Editorial Commentary: Another Call to Cure Hepatitis B

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1307-1309

  Balagopal, Ashwin ^a   Thio, Chloe L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HBV reactivation; HBV HCV coinfection; Interferon; IP 10; ISG

Indexed keywords

ANTIVIRUS AGENT; CIRCULAR DNA; CORE PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; VIRUS RNA; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; LIVER CELL; MIXED INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL CLEARANCE; VIRUS REACTIVATION; COMPLICATION; HEPATITIS B; HEPATITIS C, CHRONIC; MALE; PHYSIOLOGY;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; SIMEPREVIR; SOFOSBUVIR;

EID: 84943237636     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ475     Document Type: Note

References (23)

1. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703-11.
2. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015; 61:1304-6.
3. Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J 2012; 9:186.
4. Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol 2005; 4:100-6.
5. Wiegand SB, Jaroszewicz J, Potthoff A, et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferongamma-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect 2015; 21:710.e1-e9.
6. Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 2013; 110:3991-6.
7. Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 278: 591-607.
8. Pasquinelli C, Shoenberger JM, Chung J, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997; 25:719-27.
9. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009; 50:46-55.
10. Rodriguez-Inigo E, Bartolome J, Ortiz-Movilla N, et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCVand occult HBV infection. J Virol 2005; 79:15578-81.
11. Kandathil AJ, Graw F, Quinn J, et al. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 2013; 145:1404-13.e1-10.
12. Rodriguez-Inigo E, Mariscal L, Bartolome J, et al. Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection. J Med Virol 2003; 70:571-80.
13. Cheng PN, Liu WC, Tsai HW, Wu IC, Chang TT, Young KC. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. J Med Virol 2011; 83:602-7.
14. Graw F, Balagopal A, Kandathil AJ, et al. Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. PLoS Comput Biol 2014; 10:e1003934.
15. Dahari H, Major M, Zhang X, et al. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005; 128:1056-66.
16. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75:7059-66.
17. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-9.
18. Zeremski M, Petrovic LM, Chiriboga L, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48:1440-50.
19. Reiberger T, Aberle JH, Kundi M, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008; 13:969-76.
20. Lin JC, Habersetzer F, Rodriguez-Torres M, et al. Interferon gamma-induced protein10 kinetics in treatment-naive versus treatmentexperienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J Infect Dis 2014; 210:1881-5.
21. Serti E,Werner JM, Chattergoon M, Cox AL, Lohmann V, Rehermann B. Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. Gastroenterology 2014; 147:209-20.e3.
22. Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015; 149:190-200.e2.
23. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-2.